-

09:00:26 PM

BVXV Stock News

BVXV - Biondvax Pharmaceuticals Ltd

11/30/22 9:14 AM

Nasdaq : BVXV

earningslow float

BiondVax announces Third Quarter 2022 Financial Results and Provides Business Update

via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published

RHEA-AI

neutral

11/29/22 7:00 AM

Nasdaq : BVXV

covid-19low float

BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy

Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with inhaled placebo BiondVax’s nanosized antibodies (NanoAbs) are being formulated as a convenient

RHEA-AI

neutral

11/15/22 8:33 AM

Nasdaq : BVXV

low float

BiondVax Congratulates Dirk Görlich on $1.4 million WLA Prize in Life Sciences

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases

RHEA-AI

very positive

11/10/22 4:00 PM

Nasdaq : BVXV

low float

BiondVax Announces Plan to Implement ADS Ratio Change

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases

RHEA-AI

neutral

11/03/22 11:30 AM

Nasdaq : BVXV

conferenceslow float

BiondVax to present at Recent Advances in Fermentation Technology (RAFT) 14 Conference

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that

RHEA-AI

neutral

11/02/22 4:30 PM

Nasdaq : BVXV

low float

BiondVax provides plan to address Nasdaq compliance

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced updates

RHEA-AI

neutral

10/11/22 2:00 PM

Nasdaq : BVXV

conferenceslow float

BiondVax to present at LD Micro Investor Conference in Los Angeles

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced today that

RHEA-AI

neutral

09/30/22 7:33 AM

Nasdaq : BVXV

low float

BiondVax announces financial plans to support its ongoing NanoAb pipeline development

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) ("BiondVax"), a biotechnology company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, announced

RHEA-AI

positive

09/20/22 6:15 AM

Nasdaq : BVXV

covid-19low float

BiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today provided encouraging updates related to the

RHEA-AI

very positive

09/08/22 9:13 AM

Nasdaq : BVXV

conferenceslow float

BiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that the

RHEA-AI

neutral

1 2 3 4 5 6 Next

BVXV Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.biondvax.com
CeoRon Babecoff
Security nameBiondvax Pharmaceuticals Ltd - ADR
Issue typead
SectorManufacturing
Sic code2836
Employees2021
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressWeizmann Science Park
StateNess Ziona
CityPo Box 4143 14 Einstein Street
Zip7403618
CountryIsrael
Phone97289302529

About Biondvax Pharmaceuticals Ltd

BiondVax Pharmaceuticals Ltd. is a biopharmaceutical company focused on development and manufacturing of products for the prevention of infectious diseases. The Company had been developing M 001, a novel flu vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of flu strains. In October 2020, the Company completed a Phase 3 clinical trial of M 001 which failed to meet the trial’s primary and secondary efficacy endpoints. The company is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets.